If you are waiting for a cheaper generic version of Eliquis, here is the short version: it has been FDA-approved since December 2019, but you cannot buy it in a US pharmacy until at least April 1, 2028. That gap is not about safety or science — it is about patents and the legal settlements that resolved them. SunnyPharma is an independent health education platform; we do not sell medication, and we have no stake in whether you wait or switch. This page explains the timeline honestly and, more importantly, what you can do about your cost in the roughly 21 months until the generic arrives.
Generic apixaban (generic Eliquis) has been FDA-approved since December 2019 but is blocked from US pharmacies until April 1, 2028 by patent settlements. You may see “November 2026” cited — that is when one patent expires, not when a generic reaches your pharmacy. Until 2028, you can lower your Eliquis cost through the copay card, patient assistance, or Medicare programs — you do not have to wait, and you should never stop taking it to save money.
- Generic apixaban has been FDA-approved since December 2019 — the delay is legal, not a safety question.
- The earliest US launch is April 1, 2028, set by patent settlements and upheld in court.
- November 2026 is a patent-expiry date, not an availability date — a separate formulation patent blocks generics until 2028.
- The 2028 settlement actually shortens the wait: without it, the formulation patent would run to August 2031.
- You can lower your cost right now — copay card, patient assistance, or Medicare programs — without waiting.
- Never stop Eliquis to wait for the generic. Stopping early raises clot and stroke risk (FDA boxed warning).
When Generic Eliquis Will Actually Be Available
April 1, 2028 is the earliest date generic apixaban can legally be sold in a US pharmacy. That comes from Bristol Myers Squibb directly and was upheld by the US Court of Appeals for the Federal Circuit, though it remains subject to further appeals. The FDA approved generic apixaban from multiple manufacturers in December 2019, so the medication itself has been ready for years; what was not ready is the legal clearance to sell it.
When generics do arrive, expect the price to ease gradually rather than collapse overnight. A single early generic produces only modest savings; bigger drops follow once several manufacturers compete, likely developing over 2028 to 2029.
A note from the reviewer
A cheaper version that exists on paper but can’t be sold yet doesn’t help you this month. Use what’s actually available now. Waiting isn’t a plan.
— Dr. Elizabeth Swiggum, MD, FRCPC, FCCS, cardiologist and heart failure specialist
Why You See “November 2026” — and Why It’s Misleading
A patent expiring is not the same as a generic becoming available — and that single distinction explains almost every confusing date you will read about Eliquis.
Eliquis is protected by more than one patent. The compound patent covering apixaban itself (US 6,967,208) expires November 21, 2026, extended into May 2027 by pediatric exclusivity. That is the date most articles cite. But Bristol Myers Squibb and Pfizer also hold a separate formulation patent (US 9,326,945) running to August 24, 2031 — and that is the one that actually blocked generic entry.
Here is the part almost nobody explains: the April 2028 settlement is not purely a delay. It lets generic manufacturers enter three years before the formulation patent expires, in exchange for not pursuing further litigation. So 2028 is later than the 2026 date you may have hoped for, but considerably earlier than 2031. If you are planning your finances, plan around April 2028.
Why It’s Taking So Long When the FDA Already Approved It
FDA approval and the legal right to sell are two entirely separate things — and conflating them is the source of most frustration here.
- The FDA confirmed the generics work. In December 2019 it approved generic apixaban applications from multiple companies, verifying they are bioequivalent to brand Eliquis.
- Patents still blocked the sale. BMS and Pfizer hold follow-on patents beyond the original compound patent, and successfully defended them in litigation, including a Federal Circuit appeals ruling.
- Settlements set the launch date. Rather than continue litigating, generic makers agreed to terms that set entry at April 1, 2028 — earlier than the formulation patent would have allowed, later than they had sought.
The result is a multi-year window in which an FDA-approved, lower-cost version exists but cannot legally be sold in the US. Patient-advocacy analysts have estimated the brand earns billions in additional revenue during exactly this gap.
Be careful what you read elsewhere. Several widely-read sites currently state that generic apixaban “became available in late 2024” at $30–$80 a month, or that a generic arrives in November 2026. Both are wrong. No generic apixaban is legally sold in a US pharmacy today, and any site offering one for US delivery is selling an unapproved or counterfeit product.
What to Do About Cost Until 2028
You do not have to wait until 2028 to pay less. The right move depends on your coverage today — and for most people, one of the routes below applies immediately.
Cost & access navigator
Answer one question and we’ll point you to the specific route for your Eliquis costs today — you don’t have to wait for 2028. Nothing is stored, no signup, no medication sold.
1 How is your prescription currently covered?
2 Is your household income at or below about 4× the federal poverty level?
Roughly $60,000 for one person or $124,000 for a family of four (2026). This only decides which program to check first — you enter no numbers.
Your route
Never stop taking your blood thinner to save money. Both Eliquis and Xarelto carry a boxed warning: stopping early raises the risk of clots and stroke. Use one of the routes above, or ask your prescriber about a lower-cost alternative — don’t go without.
Educational routing only — not medical advice, not a diagnosis, and not a pharmacy. SunnyPharma does not sell or ship medication. Figures reflect 2026 program terms and can change; confirm current details on the linked pages and the manufacturer sites.
| Your situation | Best current option | Where to go |
|---|---|---|
| Commercial insurance | Manufacturer copay card (as low as $10/mo) | Eliquis Coupon & Savings Card |
| Uninsured / underinsured | Patient assistance (free if eligible) | Eliquis Patient Assistance |
| Medicare | $231 negotiated price, $2,100 Part D cap, Extra Help | Eliquis on Medicare |
| Any — clinical fit | Ask about a lower-cost alternative anticoagulant | Your prescriber |
Do not stop or ration Eliquis while you wait for the generic. Eliquis carries an FDA boxed warning: stopping it early increases the risk of blood clots and stroke. The generic is roughly 21 months away; your clot risk is immediate. If cost is forcing the decision, use the programs above or talk to your prescriber before you skip a single dose.
Generic Apixaban Already Exists Abroad
Generic apixaban is legally sold in Canada and several other countries — the same active ingredient, in the same strengths as Eliquis (commonly 2.5 mg and 5 mg), meeting Health Canada bioequivalence standards. Patent law is national, so the US block does not apply elsewhere.
Personal importation of prescription drugs into the US is not authorized by the FDA and sits in a legal gray area. A foreign generic is not a way to “skip” the 2028 wait through SunnyPharma — we do not sell, supply, or facilitate medication purchases. We mention it only so the picture is complete. If you are considering it, discuss it with your prescriber and understand the regulatory status first.
Will the Generic Actually Be Cheaper — and By How Much?
Yes, but the size of the drop depends entirely on how many manufacturers launch. With a single early generic, savings tend to be modest because there is little price pressure. As more enter, prices fall further and faster.
Reporting indicates 13 companies have filed for generic apixaban, so once the gate opens in 2028 a competitive market could develop over 2028 to 2029 — typically when the larger savings materialize. Exactly how low the price goes will depend on how many launch and how quickly.
Frequently Asked Questions
Is there a generic for Eliquis?
Not in US pharmacies. Generic apixaban was approved by the FDA in December 2019, but patent settlements block its commercial launch until April 1, 2028. Until then, US pharmacies dispense only brand-name Eliquis. Anyone claiming to sell generic Eliquis for US delivery today is selling an unapproved or counterfeit product. Generic apixaban is legally sold in other countries, including Canada.
When will generic Eliquis be available in the US?
April 1, 2028 is the earliest legal launch date, set by patent settlements between Bristol Myers Squibb, Pfizer, and the generic manufacturers, and upheld by the US Court of Appeals for the Federal Circuit. It remains subject to further appeals. A broader multi-generic market is likely to develop over 2028 to 2029, which is typically when larger price drops occur. This is a legal date, not an FDA one; the FDA approved generic apixaban in December 2019.
What can I do to lower my Eliquis cost before the generic arrives?
Your options depend on your coverage today, and none of them require waiting. With commercial insurance, the manufacturer copay card can lower your cost to as little as $10 a month. If you are uninsured or underinsured and income-eligible, the Bristol Myers Squibb Patient Assistance Foundation may provide Eliquis free. If you have Medicare, the 2026 negotiated price of $231, the $2,100 Part D out-of-pocket cap, and Extra Help all apply. Your prescriber can also discuss whether a clinically appropriate lower-cost anticoagulant fits your situation.
Should I stop taking Eliquis to wait for the generic?
No. Never stop or skip Eliquis to wait for a cheaper version. Eliquis carries an FDA boxed warning that stopping it early raises the risk of blood clots and stroke. If cost is a problem now, use the copay card, patient assistance, Medicare programs, or a prescriber-approved alternative rather than going without. The generic is roughly 21 months away; your clot and stroke risk is immediate.
How we reviewed this article:
Richard Boehme researched and wrote this guide using Bristol Myers Squibb and Pfizer public statements on the Eliquis patent litigation, the U.S. Court of Appeals for the Federal Circuit ruling, FDA generic-approval and Orange Book records, CMS Medicare Drug Price Negotiation data, and independent patent analysis from I-MAK. Dr. Elizabeth Swiggum, a cardiologist, reviewed the clinical content — including the boxed-warning caution against stopping anticoagulation for cost — for accuracy.
Sources & References
- Bristol Myers Squibb / Pfizer. Statement on the U.S. Court of Appeals for the Federal Circuit decision upholding the Eliquis patents (earliest generic launch April 1, 2028). news.bms.com; pfizer.com.
- U.S. Food & Drug Administration. Orange Book — apixaban patent and exclusivity data (US 6,967,208 compound patent, expiry Nov 21 2026 + pediatric exclusivity to May 21 2027; US 9,326,945 formulation patent, expiry Aug 24 2031). accessdata.fda.gov.
- U.S. Food & Drug Administration. First generic apixaban ANDA approvals, December 2019.
- Centers for Medicare & Medicaid Services. Medicare Drug Price Negotiation Program — Eliquis Maximum Fair Price $231 per 30-day supply, effective January 1, 2026 (announced August 2024). cms.gov.
- Bristol Myers Squibb. ELIQUIS pricing information — 2026 Medicare Part D out-of-pocket maximum of $2,100. eliquis.bmscustomerconnect.com.
- I-MAK. Overpatented, Overpriced: Eliquis patent and exclusivity analysis. i-mak.org.
- U.S. Food & Drug Administration. Personal importation of prescription drugs — policy and limitations. fda.gov.